Last Updated: 13/12/2024
Safety and immunogenicity of GSK vaccine 257049 administered on 7 schedules to African infants
Objectives
The aim of the malaria vaccine program of the MVI/GSK partnership is to develop an efficacious malaria vaccine that is deliverable through the existing system, the Expanded Program on Immunization (EPI) of WHO. This study has been designed to:
- Investigate the safety and immunogenicity of 7 infant immunization schedules of the experimental malaria vaccine integrated with an EPI regimen.
- Investigate how to maximize the antibody response to the experimental malaria vaccine.
Principal Institution
Partner Institutions
Study Design
Study type: Interventional
Enrollment: 480 participant
Primary purpose: Prevention
Allocation: Randomized
Interventional Model: Parallel assignment
Masking : Open label
NCT number: NCT01231503
Phase: Phase II
External reference
Related Resources
